These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7742035)

  • 1. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.
    Powell MF; Eastman DJ; Lim A; Lucas C; Peterson M; Vennari J; Weissburg RP; Wrin T; Kensil CR; Newman MJ
    AIDS Res Hum Retroviruses; 1995 Feb; 11(2):203-9. PubMed ID: 7742035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .
    Powell MF; Cleland JL; Eastman DJ; Lim A; Murthy K; Newman MJ; Nunberg JH; Weissburg RP; Vennari JC; Wrin T
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S105-8. PubMed ID: 7865282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a single-shot subunit vaccine for HIV-1.
    Cleland JL; Powell MF; Lim A; Barrón L; Berman PW; Eastman DJ; Nunberg JH; Wrin T; Vennari JC
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S21-6. PubMed ID: 7865303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response.
    Cleland JL; Lim A; Daugherty A; Barron L; Desjardin N; Duenas ET; Eastman DJ; Vennari JC; Wrin T; Berman P; Murthy KK; Powell MF
    J Pharm Sci; 1998 Dec; 87(12):1489-95. PubMed ID: 10189254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
    Evans TG; McElrath MJ; Matthews T; Montefiori D; Weinhold K; Wolff M; Keefer MC; Kallas EG; Corey L; Gorse GJ; Belshe R; Graham BS; Spearman PW; Schwartz D; Mulligan MJ; Goepfert P; Fast P; Berman P; Powell M; Francis D;
    Vaccine; 2001 Feb; 19(15-16):2080-91. PubMed ID: 11228380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.
    Cleland JL; Barrón L; Daugherty A; Eastman D; Kensil C; Lim A; Weissburg RP; Wrin T; Vennari J; Powell MF
    J Pharm Sci; 1996 Dec; 85(12):1350-7. PubMed ID: 8961152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems.
    Sjölander S; Hansen JE; Lövgren-Bengtsson K; Akerblom L; Morein B
    Vaccine; 1996 Mar; 14(4):344-52. PubMed ID: 8744563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
    Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
    J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.
    Boyle J; Eastman D; Millar C; Camuglia S; Cox J; Pearse M; Good J; Drane D
    Vaccine; 2007 Mar; 25(14):2541-4. PubMed ID: 17240491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120.
    Peet NM; McKeating JA; Ramos B; Klonisch T; De Souza JB; Delves PJ; Lund T
    Clin Exp Immunol; 1997 Aug; 109(2):226-32. PubMed ID: 9276516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum.
    Weissburg RP; Berman PW; Cleland JL; Eastman D; Farina F; Frie S; Lim A; Mordenti J; Nguyen TT; Peterson MR
    Pharm Res; 1995 Oct; 12(10):1439-46. PubMed ID: 8584477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QS-21 and QS-7: purified saponin adjuvants.
    Kensil CR; Wu JY; Anderson CA; Wheeler DA; Amsden J
    Dev Biol Stand; 1998; 92():41-7. PubMed ID: 9554258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates.
    Newman MJ; Wu JY; Coughlin RT; Murphy CI; Seals JR; Wyand MS; Kensil CR
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1413-8. PubMed ID: 1466970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.